VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TLX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TLXTelix Pharmaceuticals Limited
$8.96$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksTLXBalance Sheet

Telix Pharmaceuticals Limited (TLX) Balance Sheet

9Y historyFree accessUpdated daily

The capital structure has shifted dramatically towards leverage, with total debt of $837.0M driving a debt-to-equity ratio of 1.19 and making goodwill of $285.1M a dominant, risk-exposed asset on the balance sheet.

Income StatementBalance SheetCash FlowRatios

TLX Balance Sheet

Annual statement

TLX Balance Sheet

Telix Pharmaceuticals Limited (TLX) balance sheet — 9-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets487.84M330.18M918.56M224.85M173.23M47.54M93.63M58.68M35.86M49.55M
Cash & Short-Term Investments251.82M141.82M710.35M123.24M116.33M22.04M77.94M44.6M25.77M48.76M
Cash Only251.82M141.82M710.35M123.24M116.33M22.04M77.94M44.6M25.77M48.76M
Short-Term Investments0000000000
Accounts Receivable170.32M138.33M158.99M79.53M31.14M20.84M14.19M13.01M8.97M488.83K
Days Sales Outstanding-63.9374.157.77711K993.621.36K16.78K-
Inventory39.01M37.07M38.14M17.31M5.77M3.45M633K542K642.52K0
Days Inventory Outstanding16.7536.5450.933.5832.3494.78114.1577.79--
Other Current Assets26.68M00-7.66M18.29M00000
Total Non-Current Assets873.5M851.56M597.87M173.45M82.12M62.27M64.19M43.93M40.85M1.55M
Property, Plant & Equipment129.58M115.57M54.32M30.49M18.84M6.33M4.82M1.9M226.17K5.39K
Fixed Asset Turnover0.00x6.83x14.42x16.48x8.50x1.20x1.08x1.84x0.86x-
Goodwill197.44M198.92M106.65M4.85M5.52M4.1M4.22M4.22M3.14M332.49K
Intangible Assets386.95M393.71M309.49M104.82M58.98M55.73M59.19M41.95M36.31M1.18M
Long-Term Investments87.65M37.08M6.09M12.26M-5.52M0-4.22M01.14M0
Other Non-Current Assets33.87M28.82M74.58M586K-4.91M-3.88M-6.44M-4.14M1.17M35.29K
Total Assets1.36B1.18B1.52B398.3M255.35M109.81M157.82M102.61M76.71M51.09M
Asset Turnover0.00x0.67x0.52x1.26x0.63x0.07x0.03x0.03x0.00x-
Asset Growth %332.81%-22.07%280.72%55.98%132.53%-30.42%53.81%33.76%50.13%-
Total Current Liabilities242.25M231.55M330.91M157.41M85.56M37.98M19.96M10.63M8.24M1.47M
Accounts Payable168.91M71.64M68.7M32.84M16.81M11.88M5.81M6.96M3.25M275.84K
Days Payables Outstanding40.4470.6191.6763.794.131.7K1.05K999.55-26.54K
Short-Term Debt15.42M13.11M18.99M964K636.24K19K264K469K1.13M345.43K
Deferred Revenue (Current)27.53M11.47M11.25M10.99M4.94M6.14M3.23M03.64M0
Other Current Liabilities3.42M66.46M109.67M85.7M46.69M14.12M7.65M2.72M215.72K589.76K
Current Ratio2.01x1.43x2.78x1.43x2.02x1.25x4.69x5.52x4.35x33.74x
Quick Ratio1.85x1.27x2.66x1.32x1.96x1.16x4.66x5.47x4.27x33.74x
Cash Conversion Cycle-23.6829.8533.3227.659.17-205.9660.38440.73--
Total Non-Current Liabilities631.59M534.94M617.31M91.98M89.79M68.19M58.85M21.9M15.56M332.49K
Long-Term Debt504.69M391.79M551.82M8.21M3.31M095K292K596.29K0
Capital Lease Obligations150.04M56.52M8.14M7.68M6.49M1.91M1.34M1.35M00
Deferred Tax Liabilities154.87M62.81M9.38M3.92M0003.17M4.37M332.49K
Other Non-Current Liabilities24.08M23.82M44.67M60.02M79.98M43.23M57.41M17.09M10.59M0
Total Liabilities873.85M766.49M948.22M249.39M175.35M106.17M78.81M32.53M23.8M1.8M
Total Debt579.64M466.96M581.45M17.45M10.45M2.54M2.21M2.13M1.73M345.43K
Net Debt327.83M325.14M-128.9M-105.79M-105.88M-19.5M-75.74M-42.47M-24.04M-48.41M
Debt / Equity1.19x1.12x1.02x0.12x0.13x1.18x0.03x0.03x0.03x0.01x
Debt / EBITDA4.75x12.02x6.45x0.77x------
Net Debt / EBITDA2.69x8.37x-1.43x-4.68x------
Interest Coverage2.26x0.86x4.31x5.74x-181.62x-384.54x-37.61x-16.58x-1009.81x-604.57x
Total Equity487.49M415.24M568.21M148.91M80.01M2.16M79.02M70.08M52.9M49.29M
Equity Growth %274.59%-26.92%281.58%86.12%3607.46%-97.27%12.75%32.47%7.33%-
Book Value per Share1.371.231.650.460.260.010.310.300.260.39
Total Shareholders' Equity487.49M415.24M568.21M148.91M80.01M2.16M79.02M70.08M52.9M49.29M
Common Stock490.74M479.81M596.78M446.27M370.97M170.84M167.06M115.94M72.05M55.56M
Retained Earnings-110.85M-154.49M-212.96M-263.67M-272.81M-173.47M-92.96M-48.07M-20.21M-6.38M
Treasury Stock0000000000
Accumulated OCI107.61M89.92M184.4M-33.69M-18.15M4.79M4.92M2.21M1.06M109K
Minority Interest0000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Leverage driven by acquisition funding

Balance Sheet Expansion via Strategic Leverage

The balance sheet has undergone a dramatic transformation, with total assets expanding from $109.8M in 2021Q4 to $2.0B in 2026Q2, a trajectory driven primarily by a significant increase in debt to fund strategic acquisitions.

This rapid expansion signals a shift from a pre-revenue, cash-constrained biotech to a commercially active, acquisition-fueled growth platform. The primary driver is the increase in total debt from a negligible $2.5M to $837.0M, which has funded asset growth that far outpaces organic operations, as evidenced by the corresponding surge in goodwill from $4.1M to $285.1M. While this has dramatically scaled the company, it has also fundamentally altered its risk profile, moving from a virtually debt-free entity to one where leverage is a core component of its capital structure.

Leverage Shift from Equity to Strategic Debt

Telix's debt-to-equity ratio has surged from a near-zero 0.02 in 2022Q2 to 1.19 in 2026Q2, indicating a deliberate strategic shift to fund expansion through borrowing rather than solely through equity issuance.

The increase in debt to $837.0M, concurrent with a current ratio of 2.01, suggests the company has secured financing to support its growth without creating an immediate liquidity crisis. However, the jump in leverage to a D/E of 1.19, from a peer like Exelixis at 0.08, implies that future cash flows will bear a meaningful interest burden, making the durability of its newly generated operating cash flow critical to servicing this obligations. This leverage appears strategic for acquisitions but introduces refinancing risk if growth or capital markets conditions deteriorate.

Goodwill Dominance in Asset Base

Goodwill and intangible assets now constitute approximately 14% of total assets at $285.1M, a stark increase from less than 2% in 2023, highlighting an asset-heavy model built on acquisitions rather than organic asset growth.

The asset mix reveals a business model where a significant portion of value is derived from acquired entities and their associated portfolios, rather than from traditional property, plant, and equipment. With PPE Net at $187.1M, the combined goodwill and PPE represent a substantial portion of the asset base, meaning the balance sheet's value is heavily dependent on the successful integration and commercial performance of acquired assets. This concentration introduces potential impairment risk if the acquired radiopharmaceutical assets fail to meet expected commercial targets.

Adequate Liquidity Supported by Debt-Led Cash Build

The current ratio of 2.01 in 2026Q2 indicates solid short-term liquidity, but the cash position of $363.6M appears to be partially the result of debt-funded capital raises rather than purely operational generation.

While the current ratio is healthy and above the 1.0 threshold, the cash balance of $363.6M must be evaluated in the context of the company's cash burn, as prior income statement analysis indicates operating losses are being covered by non-operating items. The liquidity buffer provides a runway for ongoing commercialization and R&D, but its composition—largely derived from financing activities as suggested by the concurrent rise in debt—means investors should monitor whether future cash needs will require further borrowing or dilutive equity raises.

Goodwill Valuation Risk in a Rising Rate Environment

The most significant non-obvious risk is the potential for goodwill impairment on the $285.1M asset, which now represents over 40% of total equity and is vulnerable if the acquired radiopharmaceutical assets underperform in a higher interest rate environment.

An impairment of this magnitude would directly erode shareholder equity, potentially triggering debt covenant concerns and severely damaging the company's credit profile. Given that the goodwill likely stems from the $344.0M cash acquisition noted in the cash flow analysis, its value is intrinsically tied to the success of the acquired commercial assets. In a scenario where revenue growth stalls or interest expenses rise significantly due to refinancing the $837.0M debt load, the headroom between the D/E ratio of 1.19 and a precarious equity base narrows, making this balance sheet risk particularly acute.

TLX — Frequently Asked Questions

Quick answers to the most common questions about buying TLX stock.

What are the total assets of Telix Pharmaceuticals Limited (TLX)?

As of 2025, Telix Pharmaceuticals Limited (TLX) had total assets of $1.18B including $330.2M in current assets.

How much debt does Telix Pharmaceuticals Limited (TLX) have?

Telix Pharmaceuticals Limited (TLX) carries total debt of $467.0M, offset by $141.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Telix Pharmaceuticals Limited?

Telix Pharmaceuticals Limited (TLX) has total shareholders' equity (book value) of $415.2M ($1.23 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Telix Pharmaceuticals Limited's current ratio and liquidity?

Telix Pharmaceuticals Limited (TLX) reported a current ratio of 1.43x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.